50
ANZUP ANNUAL REPORT 2021
RESEARCH HIGHLIGHTS
Grants and Awards Infrastructure Grants Funds provided by Cancer Australia to support ANZUP infrastructure are managed by the University of Sydney NHMRC Clinical Trials Centre and therefore not reported in the financial accounts of ANZUP unless transferred in support of specific expenses incurred by ANZUP. Grants contributing to ANZUP infrastructure costs during the 2020-21 period are outlined below.
Funding Cancer Australia Infrastructure Grant: 1 July 2018 to 30 June 2021, AUD$1,500,000 awarded to ANZUP and our collaborator on the grant NHMRC CTC. During this reporting period AUD$270,750 was transferred to ANZUP and was reported in the Annual Accounts.
Research Grants Funds provided by Cancer Australia, the National Health and Medical Research Council, philanthropic funding bodies and pharmaceutical companies in support of ANZUP trial coordination are managed by the University of Sydney acting through NHRMC Clinical Trials Centre, and therefore not reported in ANZUP’s financial accounts. Funds to support ANZUP sponsored trials and site payments, insurance and other trial related costs are transferred to ANZUP and are reflected in these accounts. ANZUP grant income and expenditure during this reporting period are included in the 2020/2021 financial accounts. Grants awarded to ANZUP Cancer Trials Group during this reporting period are listed below: BCGMM: A randomised phase III trial adding mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer. Funding by Cancer Australia AUD$457,143 (2013-2018). AUD$70,000 was transferred to ANZUP and reported in the annual accounts. BL.12: A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen. Funding by NCIC Clinical Trials Group AUD$1,384,662, Specialised Therapeutics AUD$250,000 (2015-2018). During this reporting period no funds were transferred to ANZUP.
DASL-HiCaP: A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer. Funding by Bayer USD$33,777,579. During this period USD$765,000 was transferred to ANZUP and reported in the annual accounts. ENZAMET: A randomised phase III trial of Enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer. Funding by Astellas AUD$17,131,966 (2014-2020). During this reporting period USD$15,400 was transferred to ANZUP and was reported in the annual accounts. ENZA-p: A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castrationresistant prostate cancer treated with enzalutamide. Funding by Prostate Cancer Foundation of Australia AUD$4,000,000, Endocyte USD$320,000, St Vincent’s Clinic Foundation AUD$400,000, GenesisCare AUD$300,000, and Roy Morgan Research Ltd AUD$300,000 (2020-2024). During this reporting period AUD$2,333,942 was transferred to ANZUP and was reported in the annual accounts. ENZARAD: A randomised phase III trial of Enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer. Funding by Astellas AUD$11,946,080 (2014-2020). During this reporting period no funds were transferred to ANZUP. KEYPAD: A phase II trial using denosumab and pembrolizumab in clear cell renal carcinoma. Funding by Merck Sharpe Dohme and Amgen AUD$2,454,925. During this reporting period no funds were transferred to ANZUP. Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy. Funding by Cancer Australia AUD$354,764, Prostate Cancer Foundation of Australia AUD$242,331 (2015-2018). During this reporting period no funds were transferred to ANZUP.
